Tailored chemo dosing aims to boost stem cell transplant success in myeloma
NCT ID NCT04483206
First seen Jun 17, 2026 · Last updated Jun 21, 2026 · Updated 1 time
Summary
This phase 1 trial is testing a new way to dose the chemotherapy drug melphalan for people with multiple myeloma who are getting a stem cell transplant. Instead of a standard dose, the amount is personalized based on each patient's blood levels after a test dose. The goal is to find the best dose that kills cancer cells while limiting side effects like mouth sores and heart rhythm problems. The study involves 90 participants and will also check if the treatment leads to deeper cancer remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Illinois Chicago
NOT_YET_RECRUITINGChicago, Illinois, 60607, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Winship Cancer Institute of Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Melphalan (chemotherapy drug)
What this could lead to
If successful, this could lead to more precise melphalan dosing for multiple myeloma patients, potentially improving treatment effectiveness and reducing severe side effects like mouth sores.
What could go wrong
This is an early phase 1 trial with only 90 participants, so results may not apply broadly. The personalized dosing approach is experimental and may not improve outcomes or reduce toxicity as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.